Trine A. Knudsen

Roskilde, 4000, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 33 publications

Collagen Turnover Is Associated with Disease Severity, Bone Marrow Fibrosis, and the JAK2V617F Variant Allele Frequency in Myeloproliferative Neoplasms.

Collagen Turnover Is Associated with Disease Severity, Bone Marrow Fibrosis, and the JAK2V617F Variant Allele Frequency in Myeloproliferative Neoplasms.

Journal: Cancers

Published: July 10, 2026

Mathematical modeling of JAK2V617F clonal expansion in a general population cohort.

Mathematical modeling of JAK2V617F clonal expansion in a general population cohort.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: June 17, 2026

Hierarchical mathematical modelling of patients with myeloproliferative neoplasms captures interferon-α treatment responses and allows for personalised and population predictions.

Hierarchical mathematical modelling of patients with myeloproliferative neoplasms captures interferon-α treatment responses and allows for personalised and population predictions.

Journal: Mathematical biosciences

Published: January 22, 2026

The JAK2V617F and CALR mutations and risk of cancer, cardiovascular diseases, and all-cause mortality.

The JAK2V617F and CALR mutations and risk of cancer, cardiovascular diseases, and all-cause mortality.

Journal: Journal of internal medicine

Published: November 06, 2025

Aortic Aneurysm Risk and the Somatic JAK2 V617F Mutation: Insights From a Multicenter, Population-Based Cardiovascular Screening Study.

Aortic Aneurysm Risk and the Somatic JAK2 V617F Mutation: Insights From a Multicenter, Population-Based Cardiovascular Screening Study.

Journal: Circulation

Published: June 04, 2025

Statins enhance the efficacy of pegylated interferon-alfa2 in Philadelphia-negative chronic myeloproliferative neoplasms.

Statins enhance the efficacy of pegylated interferon-alfa2 in Philadelphia-negative chronic myeloproliferative neoplasms.

Journal: Blood advances

Published: April 29, 2025

Combination therapy with ruxolitinib and pegylated interferon alfa-2a in newly diagnosed patients with polycythemia vera.

Combination therapy with ruxolitinib and pegylated interferon alfa-2a in newly diagnosed patients with polycythemia vera.

Journal: Blood advances

Published: March 14, 2024

Mathematical modelling of stem and progenitor cell dynamics during ruxolitinib treatment of patients with myeloproliferative neoplasms.

Mathematical modelling of stem and progenitor cell dynamics during ruxolitinib treatment of patients with myeloproliferative neoplasms.

Journal: Frontiers in immunology

Published: February 09, 2024

JAK2V617F drives gut microbiota differences in patients with myeloproliferative neoplasms.

JAK2V617F drives gut microbiota differences in patients with myeloproliferative neoplasms.

Journal: European journal of haematology

Published: November 16, 2023

Neutrophil-to-lymphocyte ratio and all-cause mortality with and without myeloproliferative neoplasms-a Danish longitudinal study.

Neutrophil-to-lymphocyte ratio and all-cause mortality with and without myeloproliferative neoplasms-a Danish longitudinal study.

Journal: Blood cancer journal

Published: September 28, 2023

Pronounced gut microbiota signatures in patients with JAK2V617F-positive essential thrombocythemia.

Pronounced gut microbiota signatures in patients with JAK2V617F-positive essential thrombocythemia.

Journal: Microbiology spectrum

Published: September 11, 2023

Whole blood transcriptional profiling reveals highly deregulated atherosclerosis genes in Philadelphia-chromosome negative myeloproliferative neoplasms.

Whole blood transcriptional profiling reveals highly deregulated atherosclerosis genes in Philadelphia-chromosome negative myeloproliferative neoplasms.

Journal: European journal of haematology

Published: June 26, 2023

Showing 1-12 of 33

Last Updated: 09/26/2026